FDA sanctions new version of Essure:
This article was originally published in Clinica
Executive Summary
A third-generation Essure permanent birth control system developed by Conceptus has gained approval from the US FDA. Conceptus says that the new version is superior to previous models due to its revamped delivery system, which has reduced the number of steps a physician must take when placing the device in the patient's fallopian tubes. In addition to being simpler to implant, the hysteroscopic visualisation of the implant and placement markers have also been improved, and a new DryFlow Introducer, which alleviates distension fluid loss, is being packaged with the product. The Essure procedure is the only FDA-approved female sterilisation procedure to prevent 100% of pregnancies in clinical trials, said the Mountain View, California firm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.